FDA's Financial Disclosure Requirements Might Extend To Comments On Citizen Petitions
Executive Summary
Encouraging disclosure of any financial relationship with affected drug companies by those commenting on citizen petitions could be one way FDA could respond to a Senate report questioning tactics by Sanofi-Aventis in seeking to delay approval of a generic version of Lovenox (enoxaparin sodium injection), the firm's low molecular weight heparin.